AAAAAA
Results:
1-10
|
Results: 10
Authors:
Schwartzentruber, DJ
Citation: Dj. Schwartzentruber, High-dose interleukin-2 is an intensive treatment regardless of the venue of administration, CANCER J, 7(2), 2001, pp. 103-104
Authors:
Schwartzentruber, DJ
Citation: Dj. Schwartzentruber, Guidelines for the safe administration of high-dose interleukin-2, J IMMUNOTH, 24(4), 2001, pp. 287-293
Authors:
Dudley, ME
Wunderlich, J
Nishimura, MI
Yu, D
Yang, JC
Topalian, SL
Schwartzentruber, DJ
Hwu, P
Marincola, FM
Sherry, R
Leitman, SF
Rosenberg, SA
Citation: Me. Dudley et al., Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma, J IMMUNOTH, 24(4), 2001, pp. 363-373
Authors:
Marroquin, CE
White, DE
Steinberg, SM
Rosenberg, SA
Schwartzentruber, DJ
Citation: Ce. Marroquin et al., Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer, J IMMUNOTH, 23(3), 2000, pp. 387-392
Authors:
Hurst, R
White, DE
Heiss, J
Lee, DS
Rosenberg, SA
Schwartzentruber, DJ
Citation: R. Hurst et al., Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: Is craniotomy indicated?, J IMMUNOTH, 22(4), 1999, pp. 356-362
Authors:
Rosenberg, SA
Yang, JC
Schwartzentruber, DJ
Hwu, P
Marincola, FM
Topalian, SL
Seipp, CA
Einhorn, JH
White, DE
Steinberg, SM
Citation: Sa. Rosenberg et al., Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b, J CL ONCOL, 17(3), 1999, pp. 968-975
Authors:
Orenstein, JM
Feinberg, M
Yoder, C
Schrager, L
Mican, JM
Schwartzentruber, DJ
Davey, RT
Walker, RE
Falloon, J
Kovacs, JA
Miller, KD
Fox, C
Metcalf, JA
Masur, H
Polis, MA
Citation: Jm. Orenstein et al., Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient, AIDS, 13(16), 1999, pp. 2219-2229
Authors:
Rosenberg, SA
Yang, JC
Schwartzentruber, DJ
Hwu, P
Marincola, FM
Topalian, SL
Restifo, NP
Sznol, M
Schwarz, SL
Spiess, PJ
Wunderlich, JR
Seipp, CA
Einhorn, JH
Rogers-Freezer, L
White, DE
Citation: Sa. Rosenberg et al., Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine, J IMMUNOL, 163(3), 1999, pp. 1690-1695
Authors:
Nishimura, MI
Avichezer, D
Custer, MC
Lee, CS
Chen, C
Parkhurst, MR
Diamond, RA
Robbins, PF
Schwartzentruber, DJ
Rosenberg, SA
Citation: Mi. Nishimura et al., MHC class I-restricted recognition of a melanoma antigen by a human CD4(+)tumor infiltrating lymphocyte, CANCER RES, 59(24), 1999, pp. 6230-6238
Authors:
Rosenberg, SA
Zhai, YF
Yang, JC
Schwartzentruber, DJ
Hwu, P
Marincola, F
Topalian, SL
Restifo, NP
Seipp, CA
Einhorn, JH
Roberts, B
White, DE
Citation: Sa. Rosenberg et al., Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens, J NAT CANC, 90(24), 1998, pp. 1894-1900
Risultati:
1-10
|